Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of cardiovascular disease. Our vision is to develop and market products along a treatment continuum that cardiovascular disease consumers, healthcare professionals and specialized cardiovascular disease research and healthcare institutions will identify, recommend and seek. Our business strategy is to develop and commercialize proprietary compounds to address the unmet needs of patients within the cardiovascular disease market.
Forbes Medi-Tech is listed on the Toronto Stock Exchange under the symbol FMI and on NASDAQ under FMTI.
|
![](/web/20060205114404im_/http://www.forbesmedi.com/i/common2/whatsnew.jpg)
![](/web/20060205114404im_/http://www.forbesmedi.com/i/misc/reducol-logo.gif)
Reducol Press Conference Webcast - London, UK. December 20, 2005
Click here to see Tesco products with Reducol
Q3 2005 conference call
Mon Jan 23, 2006 : Forbes Medi-Tech Announces Extension of Major Ster... (more...)
Wed Jan 4, 2006 : Forbes Medi-Tech Announces Reducol(tm) Based Produ... (more...)
Tue Dec 20, 2005 : Forbes Medi-Tech Launches Cholesterol-Lowering Ing... (more...)
![](/web/20060205114404im_/http://www.forbesmedi.com/i/common2/glance.jpg)
ROB TV Interview with Charles Butt, Nov 12, 2004
Forbes VP Wins Award of Merit
ROB TV Interview with Charles Butt, Sep 10, 2004
Low Cholesterol Chocolate - CTV News with Dr. Rhonda Lowe
Recent Conference Call
Forbes In The News
|